Webinar How Clinical Trials Really Work: Roles, Responsibilities, and Regulatory Expectations
watching
WEBINARHow Clinical Trials Really Work: Roles, Responsibilities, and Regulatory Expectations
WEBINAR

How Clinical Trials Really Work: Roles, Responsibilities, and Rules

Clinical Trial System Map

April 22, 2026
1 / 32
WEBINARHow Clinical Trials Really Work: Roles, Responsibilities, and Regulatory Expectations

This webinar builds from system map to accountability under pressure

  1. 1
    Map the core parties in a trial and the duties each retains
  2. 2
    Compare sponsor, investigator, site, CRO, and IRB-IEC obligations
  3. 3
    Spot where oversight, delegation, and documentation fail in routine work
  4. 4
    Apply GCP expectations to safety, data, and consent decisions
  5. 5
    Use realistic cases to diagnose gaps and plan follow-up actions
2 / 32
WEBINARHow Clinical Trials Really Work: Roles, Responsibilities, and Regulatory Expectations
Table 1Core Trial Actors And Their Primary Responsibilities
ActorPrimary roleNon-transferable accountability
SponsorFunds, designs, oversees trialOverall trial quality and compliance
InvestigatorConducts trial at siteParticipant safety, protocol conduct
Site teamExecutes daily study tasksAccurate records, qualified performance
CRO or vendorsPerform contracted functionsTasks only, per sponsor oversight
IRB or IECReviews ethics and consentIndependent protection of participants

Framed from ICH GCP principles and common regulatory expectations across modern trials.

3 / 32
WEBINARHow Clinical Trials Really Work: Roles, Responsibilities, and Regulatory Expectations
Figure 1Clinical Trial Decisions, Evidence, And Oversight Loop
flowchart TD
 A[Protocol and risk-based design] --> B[Site execution and participant interactions]
 B --> C[Data and safety information captured]
 C --> D[Monitoring review and issue detection]
 D --> E[Sponsor oversight and corrective decisions]
 E --> F[Updates to training processes and documentation]
 F --> B
 C --> G[Regulatory and ethics reporting]
 G --> E
4 / 32
WEBINARHow Clinical Trials Really Work: Roles, Responsibilities, and Regulatory Expectations

Sponsors own the trial design, even when execution is outsourced

The sponsor decides what question the study will answer, how it will answer it, and what evidence will count as credible. Vendors can help build and run the study, but they do not inherit the sponsor's accountability for the design choices that shape participant risk and data reliability.

  • Owns protocol, amendments, and core scientific rationale
  • Sets key quality, safety, and operational expectations
  • Chooses vendors, but must define roles and interfaces clearly
  • Answers for design flaws that drive downstream noncompliance
5 / 32
WEBINARHow Clinical Trials Really Work: Roles, Responsibilities, and Regulatory Expectations
Table 2Transferred Tasks vs Retained Sponsor Accountability
AreaMay transfer taskSponsor still accountable for
Study managementCRO coordination, timelinesAdequate oversight, quality, compliance
Safety operationsPV processing, case handlingTimely review, reporting, signal oversight
Data managementEDC build, cleaning, codingData integrity, fit-for-purpose controls
MonitoringCRA visits, reportsMonitoring strategy and issue follow-up
TMF and recordsDocument filing supportComplete essential records, inspection readiness

Based on ICH GCP principles and common inspection expectations.

6 / 32
WEBINARHow Clinical Trials Really Work: Roles, Responsibilities, and Regulatory Expectations
Figure 2Sponsor Oversight Flow Across Separate Vendors
flowchart TD
 A[Sponsor governance plan] --> B[CRO study management]
 A --> C[Data management vendor]
 A --> D[Pharmacovigilance vendor]
 B --> E[Issue and metric review]
 C --> E
 D --> E
 E --> F[Escalation and CAPA]
 F --> G[Sponsor documents decisions]
7 / 32
WEBINARHow Clinical Trials Really Work: Roles, Responsibilities, and Regulatory Expectations

One weak interface can unravel an otherwise well-run study

A sponsor may have capable vendors and clean dashboards, yet still fail inspection if no one can explain who reviewed risks across the handoffs. This matters most when safety, data, and operations sit with separate partners and nobody closes the loop.

Biotech examplestudy management, DM, and PV split across vendors
Inspection questionwho integrated oversight across all three?

If the answer is fuzzy, accountability already is too

8 / 32
WEBINARHow Clinical Trials Really Work: Roles, Responsibilities, and Regulatory Expectations

Quality management and essential records are sponsor controls, not paperwork chores

Sponsors need a quality system that matches the trial's risks, complexity, and stage. That means identifying critical processes, setting review routines, tracking deviations and CAPAs, and maintaining essential records that can show what happened and why.

  • Use risk-based quality management, not generic checklists
  • Define how safety, protocol, and data issues get escalated
  • Maintain essential records that reconstruct study decisions
  • Review vendor performance with evidence, not optimism
9 / 32
WEBINARHow Clinical Trials Really Work: Roles, Responsibilities, and Regulatory Expectations

Investigators retain site accountability, even when tasks are delegated

Delegation helps a site function, but it does not move accountability away from the principal investigator. Regulators look for active oversight of participant safety, protocol conduct, and staff performance, not just a signed form in a binder.

  • The investigator remains responsible for participant safety at the site
  • Qualified staff may perform tasks, but oversight must be real and documented
  • Protocol compliance is a medical and operational duty, not a paperwork exercise
  • Sponsors and monitors can detect issues, but they do not replace investigator judgment
10 / 32
WEBINARHow Clinical Trials Really Work: Roles, Responsibilities, and Regulatory Expectations
Table 3Site duties that can be delegated versus duties that still require investigator control
Responsibility areaMay be delegatedInvestigator must retain
Participant assessmentsYes, to qualified staffMedical oversight, key decisions
Informed consent stepsParts of processOverall responsibility, adequacy
Source documentationYesAccuracy oversight, review
IP handling tasksYes, per roleControl system, compliance
Safety follow-upYes, in workflowClinical evaluation, escalation

Based on ICH GCP principles and common FDA inspection themes.

11 / 32
WEBINARHow Clinical Trials Really Work: Roles, Responsibilities, and Regulatory Expectations
Figure 3A workable oversight loop for investigator-led site conduct
flowchart TD
 A[Protocol duties assigned] --> B[Confirm staff qualification]
 B --> C[Document delegation and training]
 C --> D[Staff perform study tasks]
 D --> E[Investigator reviews safety and conduct]
 E --> F{Issue or drift found?}
 F -->|Yes| G[Retrain, document, escalate]
 F -->|No| H[Continue oversight and review]
12 / 32
WEBINARHow Clinical Trials Really Work: Roles, Responsibilities, and Regulatory Expectations

The informed consent process belongs to the investigator, not just the form

Consent is more than getting a signature before the first procedure. The investigator is responsible for ensuring the process is ethical, current, understandable, and appropriately documented, even when trained staff help conduct the discussion.

  • Consent must use the current IRB or IEC approved version
  • Participants need time, clarity, and a chance to ask questions
  • Re-consent may be required after amendments or new risk information
  • Weak consent documentation can trigger findings despite clean data
13 / 32
WEBINARHow Clinical Trials Really Work: Roles, Responsibilities, and Regulatory Expectations

Source data and investigational product control expose the site's true discipline

These are the places where routine habits either support compliance or quietly erode it. When source records are thin, training is stale, or investigational product control is loose, the site cannot easily defend what happened or why.

  • Source records should support eligibility, visits, dosing, and safety decisions
  • Entries must be attributable, legible, contemporaneous, and reviewable
  • IP receipt, storage, dispensing, and return need clear accountability
  • Incomplete retraining after amendments is a common and avoidable gap
14 / 32
WEBINARHow Clinical Trials Really Work: Roles, Responsibilities, and Regulatory Expectations

CROs extend execution capacity, but sponsors still own oversight

A CRO can run major parts of trial execution, from study management to monitoring and vendor coordination. That does not move ultimate responsibility away from the sponsor, especially for quality, safety, and compliance.

  • CRO contracts transfer tasks, not sponsor accountability
  • Scope must define decisions, approvals, and escalation points
  • Oversight has to be active, documented, and risk-based
  • Inspection questions often target the sponsor-CRO interface
15 / 32
WEBINARHow Clinical Trials Really Work: Roles, Responsibilities, and Regulatory Expectations
Table 4Common execution partners and their practical limits
PartnerTypical responsibilitiesLimits and retained accountabilities
CROStudy management, vendor coordination, reportingSponsor retains oversight and final accountability
CRA or monitorSite visits, issue follow-up, verificationCannot provide PI medical oversight
Central labSpecialized testing, specimen logisticsCannot resolve site consent failures
IRT or eCOA vendorRandomization, drug supply, participant data toolsSystem errors still require sponsor oversight
Pharmacovigilance vendorCase processing, narratives, reporting supportSponsor still owns safety system oversight

Roles vary by contract, but regulatory expectations for retained accountability do not.

16 / 32
WEBINARHow Clinical Trials Really Work: Roles, Responsibilities, and Regulatory Expectations
Figure 4Issue escalation across sponsor, CRO, site, and vendors
flowchart TD
 A[Site or vendor detects issue] --> B[CRO or functional lead triages]
 B --> C{Participant safety or data risk?}
 C -->|Yes| D[Sponsor notified immediately]
 C -->|No| E[Track and correct per plan]
 D --> F[Assign actions, owner, due date]
 E --> F
 F --> G[Monitor effectiveness and closure]
17 / 32
WEBINARHow Clinical Trials Really Work: Roles, Responsibilities, and Regulatory Expectations

Monitoring is a control activity, not a substitute for site conduct

Monitors help the sponsor assess whether sites follow the protocol, protect participants, and generate credible data. They do not take over investigator duties, and they cannot fix weak site ownership by visiting more often.

  • CRAs verify, trend, and escalate, they do not run the site
  • Monitoring may be on-site, remote, or centralized
  • High enrollment can hide weak consent or safety follow-up
  • Findings matter only if they lead to timely correction
18 / 32
WEBINARHow Clinical Trials Really Work: Roles, Responsibilities, and Regulatory Expectations

Vendor-heavy studies fail at the seams, not usually inside one function

The hardest inspections are often about interfaces, not whether each vendor did its own narrow task. A biotech using separate vendors for study management, data management, and pharmacovigilance may have competent teams and still struggle to show coherent sponsor oversight.

  • List every handoff where data, decisions, or alerts change hands
  • Define who reconciles mismatches across systems and vendors
  • Use oversight meetings to review risks, trends, and overdue actions
  • Document why issues were escalated, accepted, or closed
19 / 32
WEBINARHow Clinical Trials Really Work: Roles, Responsibilities, and Regulatory Expectations

IRB and IEC review covers risk, rights, and study changes

Ethics review is broader than approving a consent form. The committee evaluates whether the study is ethically acceptable, whether risks are reasonable, and whether participant protections match the protocol and population.

  • Review includes protocol, consent materials, recruitment, and participant-facing tools
  • The focus is risk minimization, fair selection, and protection of rights and welfare
  • Approval is conditional, it depends on the version reviewed and current study facts
  • Sites cannot treat ethics approval as a startup milestone that stays true forever
20 / 32
WEBINARHow Clinical Trials Really Work: Roles, Responsibilities, and Regulatory Expectations

Continuing review and amendments keep ethics oversight current

Common pressure points

  • Continuing review checks whether the study still supports a favorable risk-benefit balance
  • Revised consent documents must be version controlled and deployed at the right time
  • Amendments need review before use, unless a change is needed to remove immediate hazard
21 / 32
WEBINARHow Clinical Trials Really Work: Roles, Responsibilities, and Regulatory Expectations

One missed re-consent can create a study-wide documentation problem

In the oncology example, a safety follow-up gap discovered 10 days later raises more than reporting questions. It can also expose whether participants were informed promptly about new risk information, whether the IRB or IEC was notified as required, and whether the consent process still matched actual study conditions.

22 / 32
WEBINARHow Clinical Trials Really Work: Roles, Responsibilities, and Regulatory Expectations

Consent is a conversation, and re-consent has clear triggers

A signed form proves very little on its own. Regulators and inspectors look for evidence that the participant received understandable information, had a chance to ask questions, and agreed under conditions that were appropriate for the protocol and the person's circumstances.

  • Re-consent may be triggered by new risks, major amendments, or new alternatives to participation
  • Vulnerable populations need added safeguards, not just more signatures
  • The investigator retains responsibility even when trained staff support the process
  • Documentation should show who consented, when, which version, and under what circumstances
23 / 32
WEBINARHow Clinical Trials Really Work: Roles, Responsibilities, and Regulatory Expectations

ALCOA-plus turns routine records into defensible evidence

Data quality rarely fails because someone wanted bad data. It fails when ordinary work leaves a weak trail, late entry, unclear correction, or missing context. ALCOA-plus gives teams a practical test for whether a record can support participant safety and credible results.

  • Attributable, legible, contemporaneous, original, accurate are the base
  • Plus complete, consistent, enduring, and available when needed
  • A clean CRF cannot rescue weak source documentation
  • Corrections must preserve what changed, when, and by whom
24 / 32
WEBINARHow Clinical Trials Really Work: Roles, Responsibilities, and Regulatory Expectations
Table 5ALCOA-plus in common study documents
Record typeWhat good looks likeCommon failure
AE noteDate, grade, action, follow-up clearLate entry, missing attribution
Consent noteVersion, discussion, signatures matchForm signed, process undocumented
Dose recordTime, amount, hold reason recordedBackfilled timing after visit
Lab reviewClinically reviewed, action documentedResult filed, no assessment
Deviation logIssue, impact, action, closure linkedList kept, no CAPA logic

Use the principle against the actual record, not against memory of what happened.

25 / 32
WEBINARHow Clinical Trials Really Work: Roles, Responsibilities, and Regulatory Expectations
Figure 5SAE workflow with expected decision points
flowchart TD
 A[Participant event identified] --> B[Site assesses seriousness and causality]
 B --> C[Investigator ensures immediate medical oversight]
 C --> D[Site reports SAE per protocol and regulation]
 D --> E[Sponsor or PV vendor reviews case and expectedness]
 E --> F{Reportable to regulators or ethics bodies?}
 F -->|Yes| G[Expedited reporting and follow-up]
 F -->|No| H[Document, track, and trend]
 G --> I[Close loop with site and safety database]
 H --> I[Close loop with site and safety database]
26 / 32
WEBINARHow Clinical Trials Really Work: Roles, Responsibilities, and Regulatory Expectations

10 days late can turn a routine safety gap into a major finding

In the oncology example, the alarming fact is not the holiday weekend. It is that a participant was hospitalized, SAE follow-up was missed, and the gap surfaced only when the monitor found it 10 days later. Regulators often read that as a control failure, not a one-off inconvenience.

Timelines start when the site becomes aware, not when the monitor asks

Delayed follow-up weakens safety surveillance and sponsor reporting

The key question is who owned escalation coverage during the gap

27 / 32
WEBINARHow Clinical Trials Really Work: Roles, Responsibilities, and Regulatory Expectations

Deviations need impact assessment and CAPA, not just a log entry

A deviation log is only the starting point. Teams need to decide whether the event affected safety, rights, data credibility, or protocol compliance, then take proportionate corrective and preventive action. Inspection-ready habits come from closing loops while the details are still fresh.

  • Classify the deviation, then assess impact on participant and data
  • Separate immediate correction from preventive action
  • Link retraining, vendor fixes, or process changes to root cause
  • Keep essential records current so inspection readiness is daily, not theatrical
28 / 32
WEBINARHow Clinical Trials Really Work: Roles, Responsibilities, and Regulatory Expectations

Case triage gets clear when you ask three questions first

Who decides, who documents, who answers

  • Who had authority to decide the action at that moment
  • Who must answer to regulators if the process failed
  • Who had to document the event, rationale, and follow-up
29 / 32
WEBINARHow Clinical Trials Really Work: Roles, Responsibilities, and Regulatory Expectations

The holiday-weekend SAE gap shows how support can mask accountability

This scenario looks operational, but it is really about delayed medical assessment, reporting discipline, and sponsor oversight. The monitor can surface the gap, but neither the monitor nor the CRO replaces investigator medical responsibility or sponsor safety accountability.

  • Investigator must ensure participant evaluation and timely site reporting
  • Site staff may support intake, routing, and document collection
  • Sponsor must assess reporting pathways, oversight, and escalation design
  • CRA verifies and escalates, but does not own site medical decisions
30 / 32
WEBINARHow Clinical Trials Really Work: Roles, Responsibilities, and Regulatory Expectations

Gray zones appear where vendors are busy but sponsor oversight is thin

The biotech with three separate vendors may have capable partners and still fail inspection if no one can explain how risks are overseen across handoffs. Regulators usually ask less about the org chart and more about how the sponsor knew issues were identified, escalated, and closed.

  • Vendor task lists do not equal sponsor oversight evidence
  • Safety, data, and protocol signals must connect across functions
  • Training gaps after amendments often expose weak change control
  • Ask what dashboard, meeting, or metric would have caught this sooner
31 / 32
WEBINARHow Clinical Trials Really Work: Roles, Responsibilities, and Regulatory Expectations
Thanks for watching

Next step: run one accountability review on an active or recent study

  • Map who decides, who supports, who documents, who escalates
  • Test one recent event, such as an SAE, deviation, or consent change
  • Review evidence, not assumptions: logs, training, oversight, CAPA
  • Leave with named owners, due dates, and a follow-up check
32 / 32